Trial Information
Pilot, Multicenter and Prospective Study of the Natural Killer Index From Hematopoietic Stem Cell Graft at a Genotypic, Phenotypic and Functional Level
Inclusion Criteria:
- Age superior to 1 year
- Patient that will be treated by an HSC graft
- Initial pathology of recipient: acute lymphoblastic leukemia, acute myeloblastic
leukemia, chronic myeloid leukemia
Exclusion Criteria:
- Patient already included in a study with an exclusion period
- HIV + or HCV + serology during pre-graft analysis
- Patient already treated by an allograft of HSC
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Outcome Measure:
Estimate in the pilot study the percentage of different NK cell populations during hematopoietic reconstitution after HSCT with regard to the KIR and HLA genotypes of donor / recipient
Outcome Time Frame:
J60 post-HSCT
Safety Issue:
No
Principal Investigator
Françoise Mechinaud, md
Investigator Role:
Principal Investigator
Investigator Affiliation:
CHU de Nantes
Authority:
France: Ministry of Health
Study ID:
BRD 06/6-N
NCT ID:
NCT00435864
Start Date:
April 2007
Completion Date:
July 2012
Related Keywords:
- Acute Lymphoblastic Leukemia
- Acute Myeloblastic Leukemia
- Chronic Myeloid Leukemia
- recipient of a HSC graft in Acute Myeloblastic Leukemia therapy
- recipient of a HSC graft in others pathologies treated in hematology of Nantes university hospital or Angers university hospital
- donors are healthy subjects
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myeloid, Acute
- Leukemia, Myeloid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive